Daniela Degli Esposti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Daniela Degli Esposti has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Claudio Borghi
Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy
2 shared publications - Alberto Milan
Candiolo Cancer Institute, FPO—IRCCS, 10060 Candiolo, TO, Italy
1 shared publication Alberto Morganti
Chair of Internal Medicine and Hypertension Center, Ospedale S. Giuseppe, Italy
1 shared publicationAnna Capra
Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Milano
1 shared publication- Anna Maria Grandi
Medicine and Health University of New South Wales Sydney New South Wales Australia
1 shared publication - Antonello Ganau
University of Sassari
1 shared publication
Latest Publications
- Open Access
- 14 July 2023
- Published by Wiley in Phytotherapy Research
- Vol. 37 (10) , 4851-4861
Effect of dietary supplementation with Diuripres® on blood pressure, vascular health, and metabolic parameters in individuals with high‐normal blood pressure or stage I hypertension: The CONDOR randomized clinical study
Our aim was to evaluate if a nutritional intervention with a dietary supplement (Diuripres & REG;) containing magnesium, standardized extract of orthosiphon, hawthorn, and hibiscus could positively affect blood pressure (BP), vascular health, and metabolic parameters in 60 individuals with high-normal BP or stage I hypertension. Participants followed a low-fat low-sodium Mediterranean diet for 4 weeks before being randomly allocated to 8-week treatment with two pills each day of either Diuripres & REG; or placebo. Diuripres & REG; significantly decreased systolic BP compared to placebo after 4 weeks (3.1 & PLUSMN; 0.8 mmHg; p < 0.05) and more consistently after 8 weeks (3.4 & PLUSMN; 0.9 mmHg; p < 0.05). At 8-week follow-up, after correction for multiple testing, dietary supplementation with Diuripres & REG; was associated with significant improvements in diastolic BP (-3.1 & PLUSMN; 0.6 mmHg; p < 0.05), aortic BP (-4.3 & PLUSMN; 0.4 mmHg; p < 0.05), and high-sensitivity C-reactive protein (hs-CRP; 0.04 & PLUSMN; 0.01 mg/dL; p < 0.05) in comparison with baseline. The reductions in diastolic BP (--3.8 & PLUSMN; 0.7 mmHg; p < 0.05), aortic BP (-5.2 & PLUSMN; 1.0 mmHg; p < 0.05), and hs-CRP (-0.03 & PLUSMN; 0.01 mg/dL; p < 0.05) were also significant compared to placebo. Therefore, our study shows that dietary supplementation with Diuripres & REG; may be useful in individuals with high-normal BP or stage I hypertension.
- 14 July 2023
- Published by Wiley in Phytotherapy Research
- Vol. 37 (10) , 4851-4861
Open AccessEffect of dietary supplementation with Diuripres® on blood pressure, vascular health, and metabolic parameters in individuals with high‐normal blood pressure or stage I hypertension: The CONDOR randomized clinical study
Our aim was to evaluate if a nutritional intervention with a dietary supplement (Diuripres & REG;) containing magnesium, standardized extract of orthosiphon, hawthorn, and hibiscus could positively affect blood pressure (BP), vascular health, and metabolic parameters in 60 individuals with high-normal BP or stage I hypertension. Participants followed a low-fat low-sodium Mediterranean diet for 4 weeks before being randomly allocated to 8-week treatment with two pills each day of either Diuripres & REG; or placebo. Diuripres & REG; significantly decreased systolic BP compared to placebo after 4 weeks (3.1 & PLUSMN; 0.8 mmHg; p < 0.05) and more consistently after 8 weeks (3.4 & PLUSMN; 0.9 mmHg; p < 0.05). At 8-week follow-up, after correction for multiple testing, dietary supplementation with Diuripres & REG; was associated with significant improvements in diastolic BP (-3.1 & PLUSMN; 0.6 mmHg; p < 0.05), aortic BP (-4.3 & PLUSMN; 0.4 mmHg; p < 0.05), and high-sensitivity C-reactive protein (hs-CRP; 0.04 & PLUSMN; 0.01 mg/dL; p < 0.05) in comparison with baseline. The reductions in diastolic BP (--3.8 & PLUSMN; 0.7 mmHg; p < 0.05), aortic BP (-5.2 & PLUSMN; 1.0 mmHg; p < 0.05), and hs-CRP (-0.03 & PLUSMN; 0.01 mg/dL; p < 0.05) were also significant compared to placebo. Therefore, our study shows that dietary supplementation with Diuripres & REG; may be useful in individuals with high-normal BP or stage I hypertension.
- 26 January 2011
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 33 (3) , 192-201
Self-Reported Weight and Height: Implications for Left Ventricular Hypertrophy Detection. An Italian Multi-Center Study
We examined the difference between self-reported and measured body size values and their impact on detection of left ventricular hypertrophy (LVH) by echocardiographic LV mass indexation. A total of 1963 subjects referred by their practitioners for routine echocardiographic examination to nine outpatient echocardiographic laboratories across Italy were included in the study. Left ventricular hypertrophy was defined according to two gender- specific criteria as: A) Left ventricular mass (LVM) index ≥49 g/h(2.7) in men and ≥45 g/h(2.7) in women; B) LVM index ≥125 g/m(2) in men and ≥110 g/m(2) in women. Prevalence of LVH was calculated by indexing LVM to both self-reported and measured anthropometric values. In the whole population, LVH tended to be underestimated by self-reported values by 5.4% according to criterion A (48.5% vs. 53.9%, p < 0.001) and by 1.2% according to criterion B (29.6% vs. 30.8%, p < 0.01); similar findings were observed in the hypertensive subgroup encompassing one-half of the sample. Underestimation of LVH was more pronounced in older patients than in younger patients: 8.6% vs. 3.2% (p < 0.001) by criterion A, 3.1% vs. 0.1% (p < 0.001) by criterion B, in women than in men (8.6% vs. 3.3% (p < 0.001) by criterion A and 1.8% vs. 0.5% (p < 0.01) by criterion B. In a sample of outpatients attending echocardiographic laboratories, LVH is misclassified when left ventricular mass is normalized to self-reported weight and height. The error is related to the clinical characteristics of patients and is more pronounced when LVM is normalized to height(2.7).
- 26 January 2011
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 33 (3) , 192-201
Self-Reported Weight and Height: Implications for Left Ventricular Hypertrophy Detection. An Italian Multi-Center Study
We examined the difference between self-reported and measured body size values and their impact on detection of left ventricular hypertrophy (LVH) by echocardiographic LV mass indexation. A total of 1963 subjects referred by their practitioners for routine echocardiographic examination to nine outpatient echocardiographic laboratories across Italy were included in the study. Left ventricular hypertrophy was defined according to two gender- specific criteria as: A) Left ventricular mass (LVM) index ≥49 g/h(2.7) in men and ≥45 g/h(2.7) in women; B) LVM index ≥125 g/m(2) in men and ≥110 g/m(2) in women. Prevalence of LVH was calculated by indexing LVM to both self-reported and measured anthropometric values. In the whole population, LVH tended to be underestimated by self-reported values by 5.4% according to criterion A (48.5% vs. 53.9%, p < 0.001) and by 1.2% according to criterion B (29.6% vs. 30.8%, p < 0.01); similar findings were observed in the hypertensive subgroup encompassing one-half of the sample. Underestimation of LVH was more pronounced in older patients than in younger patients: 8.6% vs. 3.2% (p < 0.001) by criterion A, 3.1% vs. 0.1% (p < 0.001) by criterion B, in women than in men (8.6% vs. 3.3% (p < 0.001) by criterion A and 1.8% vs. 0.5% (p < 0.01) by criterion B. In a sample of outpatients attending echocardiographic laboratories, LVH is misclassified when left ventricular mass is normalized to self-reported weight and height. The error is related to the clinical characteristics of patients and is more pronounced when LVM is normalized to height(2.7).
- 1 May 1992
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 8 (S1) , 129-133
ACE-inhibitors and atherosclerosis
The involvement of the circulating and local renin-angiotensin system in atherosclerotic process has been hypothesized on the basis of experimental data showing presence and specific actions of the components of this system in the vascular wall. In particular, angiotensin II may participate in well known events in atherogenesis as the control of smooth muscle cell growth and proliferation. Recent studies have shown an effect of angiotensin converting enzyme (ACE) inhibition on the development of atherosclerosis in animal models. Captopril and cilazapril prevent myointimal proliferation after vascular injury in rat. Captopril reduces aortic cholesterol content and percentage intmal aortic surface covered by lesions in Watanabe heritable hyperlipidemic rabbits. Captopril also significantly reduces the progression of carotid and coronary lesions in monkeys fed a high cholesterol diet. In addition, a role for converting enzyme inhibitors in reducing aortic and microvascular growth either in hypertensive or normotensive rats has been demonstrated. It is possible that ACE-inhibitors prevent angiotensin II-induced vascular proliferation and thereby suppress the development of atherosclerosis in animals. It is also conceivable that the blood pressure effects of ACE-inhibitors could play a role in the antiatherosclerotic effect shown by these drugs, even though this explanation cannot be addressed by studies dealing with normotensive animals. Then, other mechanisms could be involved, including hypothesized effects of blockade of the renin-angiotensin system on sympathetic nervous system activity, regulation of vascular growth factors and insulin sensivity. The clinical significance of these experimental findings is unknown. Molecular mechanisms by which the renin-angiotensin system can act on atherosclerosis pathogenesis and the influence of ACE-inhibitors on the course of arterial diseases in humans ought to be important subjects of future investigations.
- 1 May 1992
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 8 (S1) , 129-133
ACE-inhibitors and atherosclerosis
The involvement of the circulating and local renin-angiotensin system in atherosclerotic process has been hypothesized on the basis of experimental data showing presence and specific actions of the components of this system in the vascular wall. In particular, angiotensin II may participate in well known events in atherogenesis as the control of smooth muscle cell growth and proliferation. Recent studies have shown an effect of angiotensin converting enzyme (ACE) inhibition on the development of atherosclerosis in animal models. Captopril and cilazapril prevent myointimal proliferation after vascular injury in rat. Captopril reduces aortic cholesterol content and percentage intmal aortic surface covered by lesions in Watanabe heritable hyperlipidemic rabbits. Captopril also significantly reduces the progression of carotid and coronary lesions in monkeys fed a high cholesterol diet. In addition, a role for converting enzyme inhibitors in reducing aortic and microvascular growth either in hypertensive or normotensive rats has been demonstrated. It is possible that ACE-inhibitors prevent angiotensin II-induced vascular proliferation and thereby suppress the development of atherosclerosis in animals. It is also conceivable that the blood pressure effects of ACE-inhibitors could play a role in the antiatherosclerotic effect shown by these drugs, even though this explanation cannot be addressed by studies dealing with normotensive animals. Then, other mechanisms could be involved, including hypothesized effects of blockade of the renin-angiotensin system on sympathetic nervous system activity, regulation of vascular growth factors and insulin sensivity. The clinical significance of these experimental findings is unknown. Molecular mechanisms by which the renin-angiotensin system can act on atherosclerosis pathogenesis and the influence of ACE-inhibitors on the course of arterial diseases in humans ought to be important subjects of future investigations.